Free Trial
NASDAQ:ONC

Beigene (ONC) Stock Price, News & Analysis

Beigene logo
$268.45 +1.06 (+0.40%)
As of 01:39 PM Eastern

About Beigene Stock (NASDAQ:ONC)

Key Stats

Today's Range
$264.43
$275.25
50-Day Range
N/A
52-Week Range
$126.97
$287.88
Volume
266,021 shs
Average Volume
444,948 shs
Market Capitalization
$26.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$310.00
Consensus Rating
Buy

Company Overview

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Remove Ads

Beigene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

ONC MarketRank™: 

Beigene scored higher than 26% of companies evaluated by MarketBeat, and ranked 858th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Beigene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Beigene has only been the subject of 3 research reports in the past 90 days.

  • Read more about Beigene's stock forecast and price target.
  • Earnings Growth

    Earnings for Beigene are expected to grow in the coming year, from ($5.82) to $0.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Beigene is -32.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Beigene is -32.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Beigene has a PEG Ratio of 7.73. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Beigene has a P/B Ratio of 7.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ONC.
  • Dividend Yield

    Beigene does not currently pay a dividend.

  • Dividend Growth

    Beigene does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ONC.
  • News Sentiment

    Beigene has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Beigene this week, compared to 7 articles on an average week.
  • Search Interest

    Only 1 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Beigene to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Beigene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $270,454,249.00 in company stock.

  • Percentage Held by Insiders

    Only 7.43% of the stock of Beigene is held by insiders.

  • Percentage Held by Institutions

    48.55% of the stock of Beigene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Beigene's insider trading history.
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beigene and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

While Markets Slide, These "Genesis Cog" Trades Are Up Double-Digits
While most investors are struggling in today's volatile market, a small group of traders are quietly booking consistent gains. Just last week, our Genesis Cog subscribers captured an 11.51% gain shorting JEF, another 8.57% on CAKE, and 4.78% on RJF—all while the broader indexes continued their downward trend.
Contrasting Beigene (ONC) & The Competition
Bank of America Securities Keeps Their Buy Rating on BeiGene (ONC)
BeiGene price target raised to $259 from $207 at Bernstein
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

Beigene's stock was trading at $223.50 at the beginning of the year. Since then, ONC shares have increased by 20.1% and is now trading at $268.45.
View the best growth stocks for 2025 here
.

Beigene, Ltd. (NASDAQ:ONC) issued its earnings results on Thursday, February, 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by $0.55. The business earned $1.13 billion during the quarter, compared to analysts' expectations of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative trailing twelve-month return on equity of 25.12%.

Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
2/27/2025
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONC
Previous Symbol
NASDAQ:ONC
Web
N/A
Fax
N/A
Employees
10,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$310.00
High Stock Price Target
$348.00
Low Stock Price Target
$259.00
Potential Upside/Downside
+17.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
7.73
Net Income
$-881,710,000.00
Pretax Margin
-24.07%

Debt

Sales & Book Value

Annual Sales
$3.81 billion
Price / Cash Flow
N/A
Book Value
$37.10 per share
Price / Book
7.14

Miscellaneous

Free Float
90,588,000
Market Cap
$26.15 billion
Optionable
N/A
Beta
0.65
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ONC) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners